site map  

 

 

 

 

 

 

 


QUESTIONS?

+1 (802) 878-1777

hti@haemtech.com


 

 

 

 

 

 

 

 

ORDERING

Human Proteins

Bovine Proteins

Mouse Proteins

Other Species

Inhibitors

Substrates

Antibodies

Sample Collection Tubes

Deficient Plasmas

Assay Kits

Pricing

HOME PAGE

 

 

 

 

 

 

 

 

QUESTIONS?

+1 (802) 878-1777

hti@haemtech.com

 von Willebrand Factor

MULTIMERIC STRUCTURE OF VON WILLEBRAND FACTOR The formation of a 1.8 MDa von Willebrand factor (vWF) multimer with bound factor VIII is illustrated. Each vWF monomer (Mr=260,000) contains a factor VIII binding site near the NH2-terminal end of the molecule. The monomers are joined end-to-end (NH2 to NH2 and COOH to COOH) by disulfide bonds to form large multimers. The mature multimers can bind one factor VIII molecule per monomeric subunit.

 

PURCHASING AND PRODUCT INFORMATION

 

Catalog Number

HCVWF-0190

HCVWF-0191

Description

Human von Willebrand Factor

Human vWF - Factor VIII Free

Size

100 g

100 g

Formulation

25 mM NaCitrate, 100 mM NaCl, 100 mM Glycine, pH 6.8

Storage

-80oC

Purity

>95% by SDS-PAGE

NOT tissue/cell culture grade

Activity Determination

N/A

Shelf Life (properly stored)

12 months

Sample Gel Information:

Gel: Novex 4-12% Bis-Tris

Load: Human von Willebrand Factor, 1 g per lane

Buffer: MOPS

Standard: SeeBluePlus 2; Myosin (191 kDa), Phosphorylase B (97 kDa), BSA (64 kDa), Glutamic Dehydrogenase (51 kDa), Alcohol Dehydrogenase (39 kDa), Carbonic Anhydrase (28 kDa), Myoglobin Red (19 kDa), Lysozyme (14 kDa)

 

Sample publications referencing our Factor von Willebrand Factor:

  1. Garcia, A., et al., Blood. 2005 November 15; 106(10): 34103414. (fibrinogen receptor activation)

  2. Liu, J., et al., Blood. 2005 October 15; 106(8): 27502756. (VWF-induced signaling)

  3. Pergolizzi, R., Blood. 2006 August 1; 108(3): 862869. (mouse vWF disease)

This publication list is not all encompassing, and is only meant to provide limited examples of how Haematologic Technologies' products are used.  We encourage you to search the literature for other examples pertinent to your experimentation, and to contact us with any technical questions.

U.S. Pricing

Product inquiry

SAMPLE DATA SHEET

ORDER NOW!

 

Overview of von Willebrand Factor

Von Willebrand factor (vWF) is a multimeric plasma glycoprotein that is required for normal hemostatic platelet plug formation (1-8). The mature plasma protein is composed of apparently identical subunits (Mr=260,000) which are held together by disulfide bonds. The circulating vWF molecule ranges in size from dimers (Mr=520,000) to extremely large multimers (Mr>10,000,000). During normal hemostasis, the larger multimers of vWF are responsible for facilitating platelet plug formation by forming a bridge between platelet glycoprotein IB and exposed collagen in the subendothelium (9-14). Either a lack of vWF protein or the presence of abnormalities which result in decreased polymerization may cause a loss of biological activity which is characteristic of von Willebrand's disease. 
In addition to its role in platelet plug formation, vWF is also responsible for the binding and transport of factor VIII (antihemophilic factor) in plasma (15). It appears that this latter event is responsible for both the stability and effective delivery of functional factor VIII. Studies indicate that factor VIII binds to the NH2-terminal portion of the mature vWF subunit with a stoichiometry of one factor VIII molecule per vWF monomer (16,17). 
The single chain vWF monomer contains a large number of cysteine residues at both the NH2-terminal and COOH-terminal ends, which are involved in the multimer formation. Carbohydrate analyses indicate that nearly 15% of the mass of vWF is contributed by carbohydrate (18). It appears that the carbohydrate serves to protect vWF from proteolysis, but is not necessary for functional activity or multimer formation. 

vWF is prepared from citrated human plasma using a combination of the procedures described by Thorell (19), and Lollar (20). A factor VIII free vWF preparation, further purified to ensure removal of factor VIII procoagulant activity, is also available. The preparations are >95% pure as judged by SDS-PAGE under reducing conditions, and consist of large multimers as determined by electrophoresis in SDS/agarose gels. The protein is shipped frozen in 0.025M sodium citrate, 0.1M glycine, 0.1M NaCl, pH 6.8, for storage at -70C. 

 

Properties of von Willebrand Factor

Localization:

Plasma and subendothelium

Mode of action:

facilitates platelet plug formation by forming a bridge between platelet glycoprotein IB and exposed collagen in the subendothelium; also binds and transports factor VIII

Molecular weight:

260,000 to >10,000,000 (1-8)

Isoelectric point:

5.7-5.9 (21)

Extinction coefficient:

Not Applicable; concentration determined by total protein assay.

Concentration in plasma

10 micrograms/mL (21)

Structure:

multimeric protein composed of identical 260,000 molecular weight subunits

Percent carbohydrate:

approximately 15% (18)

 

References 
1. Hoyer, L.W., Blood, 58, 1 (1981). 
2. Ruggeri, Z.M. and Zimmerman, T.S., J. Clin. Invest., 65, 1318 (1980). 
3. Zimmerman, T.S., et al., Proc. Natl. Acad. Sci. USA, 72, 5121 (1975). 
4. Hoyer, L.W. and Shainoff, J.R., Blood, 55, 1056 (1980). 
5. Counts, R.B., et al., J. Clin. Invest., 62, 702 (1979). 
6. Perret, B.A., et al., Biochim. Biophys. Acta, 578, 164 (1979). 
7. Weinstein, M. and Deykin, D., Blood, 53, 1095 (1979). 
8. Meyer, D., et al., J. Lab. Clin. Invest., 95, 590 (1980). 
9. Okumura, T. and Jameison, G.A., Thromb. Res., 8, 701 (1976). 
10. Nachman, R.L., et al., J. Clin. Invest., 59, (1977). 
11. Jenkins, C.S.P., et al., J. Clin. Invest., 57, 112 (1976). 
12. Santoro, S.A., Thromb. Res., 21, 689 (1981). 
13. Santoro, S.A. and Cowan, J.F., Collagen Relat. Res., 2, 31 (1982). 
14. Morton, L.F., et al., Thromb. Res., 32, 545 (1983). 
15. Tuddenham, E.G.D., et al., Br. J. Haematol., 52, 259 (1982). 
16. Foster, P.A., et al., J. Biol. Chem., 262, 8443 (1987). 
17. Parker, C.G. and Lollar, P., J. Biol. Chem., 262, 17572 (1987). 
18. Federici, A.B., et al., J. Clin. Invest., 74, 2049 (1984). 
19. Thorell, L. and Blomback, B., Thromb. Res., 35, 431 (1984). 
20. Lollar, P., et al., J. Biol. Chem., 263, 10451 (1988). 

21. Furlan, M., Human Protein Data (A. Haeberli, ed.) VCH Verlagsges, mbH, Weinheim

PRODUCTS ORDERING SERVICES ABOUT US TECH NOTES CONTACT

 

 

© 2009 Haematologic Technologies, Inc. All Rights Reservedspacer